FDA Bans Oscar Bobo for Five Years Over Mislabeled Drug Imports
Published Date: 5/15/2026
Notice
Summary
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Five‑Year Drug Import Debarment
Oscar Bobo is banned for 5 years from importing or offering to import any drug into the United States, effective May 15, 2026. FDA found that between April 5, 2019 and September 3, 2024 he imported or offered for import 8 parcels containing 10 products (5,970 tablets) that were misbranded, and he waived his right to a hearing by not responding by March 25, 2026. Mr. Bobo may apply at any time for termination of the debarment under section 306(d)(1) of the FD&C Act by submitting an application as directed in the notice.
Importing for Debarred Person Is Prohibited
During Mr. Bobo's 5-year debarment, importing or offering for import any drug "by, with the assistance of, or at the direction of" Oscar Bobo is a prohibited act under section 301(cc) of the FD&C Act, effective May 15, 2026. That prohibition applies to conduct during the debarment period and may expose anyone who assists or acts at his direction to enforcement consequences.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2026-09766 — Notice of Final Federal Agency Actions on Proposed Transportation Project in State Florida
Florida’s Department of Transportation is ready to upgrade Clearlake Road from a two-lane street to a safer, four-lane road with a cool new roundabout and bike-friendly paths on both sides. If you want to challenge these changes, you’ve got until October 13, 2026, to speak up. This project promises smoother traffic and better travel for everyone in the area!
Next: 2026-09768 — Notice of Determinations; Culturally Significant Objects Being Imported for Exhibition-Determinations: “Tarot! Renaissance Roots, Modern Visions” Exhibition
The U.S. government has approved special Tarot art pieces from other countries to be shown temporarily at The Morgan Library & Museum in New York and possibly other places. This means the exhibition is officially recognized as important to culture and the nation. No costs or deadlines affect the public, but the show highlights cool Renaissance and modern Tarot art for everyone to enjoy.